SEHK:1093Pharmaceuticals
CSPC Pharmaceutical Group (SEHK:1093) Valuation Check After New Long-Acting Obesity And Pain Drug Trial Approvals
CSPC Pharmaceutical Group (SEHK:1093) has received regulatory clearance for two long-acting drug candidates, including a monthly GLP-1/GIP injection in the US and a week-long ropivacaine pain therapy trial in China.
See our latest analysis for CSPC Pharmaceutical Group.
These trial approvals arrive after a strong 116.18% 1-year total shareholder return and a 25.16% 90-day share price return, although the 30-day share price return of 6.16% and recent 7-day weakness suggest shorter term...